-+ 0.00%
-+ 0.00%
-+ 0.00%

Amneal lifts 2026 adjusted EBITDA outlook to $740 million-$770 million

PUBT·04/22/2026 11:02:26
Listen to the news
Amneal lifts 2026 adjusted EBITDA outlook to $740 million-$770 million
  • Amneal updated FY 2026 guidance to net revenue of $3.05 billion-$3.15 billion.
  • Adjusted EBITDA outlook increased to $740 million-$770 million.
  • Adjusted diluted EPS forecast raised to $0.95-$1.05.
  • Operating cash flow expectation lifted to $350 million-$400 million.
  • Preliminary combined-company outlook assumes Kashiv BioSciences acquisition closes in 2H 2026, targeting 2027 net revenue of $3.3 billion-$3.5 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amneal Pharmaceuticals Inc. published the original content used to generate this news brief on April 22, 2026, and is solely responsible for the information contained therein.